Nicholas M. Quaife

Nicholas M. Quaife

Auto-generated profile, based on publicly available information

Nicholas M. Quaife

National Heart and Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, Du Cane Road, London, W12 0NN, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Cell
Verified
Journal Article
Closed access
SHSebastiaan van Heesch
Sebastiaan van Heesch
FWFranziska Witte
Franziska Witte
VSValentin Schneider-Lunitz
Valentin Schneider-Lunitz
JSJana F. Schulz
Jana F. Schulz
EAEleonora Adami
Eleonora Adami
NHNorbert Hubner
Norbert Hubner

27 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NWNicola Whiffin
Nicola Whiffin
KKKonrad J. Karczewski
Konrad J. Karczewski
XZXiaolei Zhang
Xiaolei Zhang
SCSonia Chothani
Sonia Chothani
MSMiriam J. Smith
Miriam J. Smith
JWJames S. Ware
James S. Ware
Upstream open reading frames (uORFs) are tissue-specific cis-regulators of protein translation. Isolated reports have shown that variants that create or disrupt uORFs can cause disease. Here, in a systematic genome-wide study using 15,708 whole genome sequences, we show that variants that create new upstream start codons, and variants disrupting stop sites of existing uORFs, are under strong negative selection. This selection signal is significantly stronger for variants arising upstream of genes intolerant to loss-of-function variants. Furthermore, variants creating uORFs that overlap the coding sequence show signals of selection equivalent to coding missense variants. Finally, we identify specific genes where modification of uORFs likely represents an important disease mechanism, and report a novel uORF frameshift variant upstream of NF2 in neurofibromatosis. Our results highlight uORF-perturbing variants as an under-recognised functional class that contribute to penetrant human disease, and demonstrate the power of large-scale population sequencing data in studying non-coding variant classes.

10 September 2019 in Circulation
Verified
Journal Article
Open access
PDF file
SCSonia Chothani
Sonia Chothani
SSSebastian Schäfer
Sebastian Schäfer
EAEleonora Adami
Eleonora Adami
SVSivakumar Viswanathan
Sivakumar Viswanathan
AWAnissa A Widjaja
Anissa A Widjaja
OROwen J.L. Rackham
Owen J.L. Rackham
Background: Fibrosis is a common pathology in many cardiac disorders and is driven by the activation of resident fibroblasts. The global posttranscriptional mechanisms underlying fibroblast-to-myofibroblast conversion in the heart have not been explored. Methods: Genome-wide changes of RNA transcription and translation during human cardiac fibroblast activation were monitored with RNA sequencing and ribosome profiling. We then used RNA-binding protein-based analyses to identify translational regulators of fibrogenic genes. The integration with cardiac ribosome occupancy levels of 30 dilated cardiomyopathy patients demonstrates that these posttranscriptional mechanisms are also active in the diseased fibrotic human heart. Results: We generated nucleotide-resolution translatome data during the transforming growth factor β1-driven cellular transition of human cardiac fibroblasts to myofibroblasts. This identified dynamic changes of RNA transcription and translation at several time points during the fibrotic response, revealing transient and early-responder genes. Remarkably, about one-third of all changes in gene expression in activated fibroblasts are subject to translational regulation, and dynamic variation in ribosome occupancy affects protein abundance independent of RNA levels. Targets of RNA-binding proteins were strongly enriched in posttranscriptionally regulated genes, suggesting genes such as MBNL2 can act as translational activators or repressors. Ribosome occupancy in the hearts of patients with dilated cardiomyopathy suggested the same posttranscriptional regulatory network was underlying cardiac fibrosis. Key network hubs include RNA-binding proteins such as Pumilio RNA binding family member 2 ( PUM2 ) and Quaking ( QKI ) that work in concert to regulate the translation of target transcripts in human diseased hearts. Furthermore, silencing of both PUM2 and QKI inhibits the transition of fibroblasts toward profibrotic myofibroblasts in response to transforming growth factor β1. Conclusions: We reveal widespread translational effects of transforming growth factor β1 and define novel posttranscriptional regulatory networks that control the fibroblast-to-myofibroblast transition. These networks are active in human heart disease, and silencing of hub genes limits fibroblast activation. Our findings show the central importance of translational control in fibrosis and highlight novel pathogenic mechanisms in heart failure.

27 May 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NWNicola Whiffin
Nicola Whiffin
IAIrina M. Armean
Irina M. Armean
AKAaron Kleinman
Aaron Kleinman
JMJamie L. Marshall
Jamie L. Marshall
EMEric V. Minikel
Eric V. Minikel
DMDaniel G. MacArthur
Daniel G. MacArthur
Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF variants) provide natural in vivo models of human gene inactivation and can be valuable indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes1,2. Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson’s disease3,4, suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. While preclinical studies in model organisms have raised some on-target toxicity concerns5–8, the biological consequences of LRRK2 inhibition have not been well characterized in humans. Here, we systematically analyze pLoF variants in LRRK2 observed across 141,456 individuals sequenced in the Genome Aggregation Database (gnomAD)9, 49,960 exome-sequenced individuals from the UK Biobank and over 4 million participants in the 23andMe genotyped dataset. After stringent variant curation, we identify 1,455 individuals with high-confidence pLoF variants in LRRK2. Experimental validation of three variants, combined with previous work10, confirmed reduced protein levels in 82.5% of our cohort. We show that heterozygous pLoF variants in LRRK2 reduce LRRK2 protein levels but that these are not strongly associated with any specific phenotype or disease state. Our results demonstrate the value of large-scale genomic databases and phenotyping of human loss-of-function carriers for target validation in drug discovery.

18 August 2017 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
FPFilippo Perbellini
Filippo Perbellini
SWSamuel A Watson
Samuel A Watson
MSMartina Scigliano
Martina Scigliano
SASamha Alayoubi
Samha Alayoubi
STSebastian Tkach
Sebastian Tkach
Cesare M. N. TerraccianoCesare M. N. Terracciano
Cesare M. N. Terracciano
Cardiac fibroblasts (CFs) are considered the principal regulators of cardiac fibrosis. Factors that influence CF activity are difficult to determine. When isolated and cultured in vitro, CFs undergo rapid phenotypic changes including increased expression of α-SMA. Here we describe a new model to study CFs and their response to pharmacological and mechanical stimuli using in vitro cultured mouse, dog and human myocardial slices. Unloading of myocardial slices induced CF proliferation without α-SMA expression up to 7 days in culture. CFs migrating onto the culture plastic support or cultured on glass expressed αSMA within 3 days. The cells on the slice remained αSMA(−) despite transforming growth factor-β (20 ng/ml) or angiotensin II (200 µM) stimulation. When diastolic load was applied to myocardial slices using A-shaped stretchers, CF proliferation was significantly prevented at Days 3 and 7 (P < 0.001). Myocardial slices allow the study of CFs in a multicellular environment and may be used to effectively study mechanisms of cardiac fibrosis and potential targets.

1 October 2012 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
NQNicholas M Quaife
Nicholas M Quaife
OWOliver Watson
Oliver Watson
TCTimothy James Chico
Timothy James Chico